ArticleImmunoHorizons2026
Consequences of the perivascular niche remodeling for tumoricidal T-cell trafficking into metastasis of ovarian cancer.
Article in ImmunoHorizons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Update of
Authors and funding
12 authors.
Funding
Abstract
Aberrant angiogenesis in ovarian cancer (OC), driven by excessive vascular endothelial growth factor (VEGF) and other proangiogenic mediators, gives rise to structurally and functionally abnormal tumor vasculature that hinders effective T-cell infiltration. To overcome these barriers, we investigated how modulation of the perivascular niche influences antitumor T-cell trafficking and function in OC. T cells expressing a rearranged TCR transgene specific for SV40 T antigen (TAG) were adoptively transferred into TAG+ MOVCAR 5009 ovarian tumor-bearing SCID mice or syngeneic TgMISIIR-TAg-Low transgenic mice, which express TAG as a self-antigen in the fallopian tube epithelium. Transfers were performed either alone or following treatment with an oncolytic vaccinia virus expressing a CXCR4 antagonist (OV-CXCR4-A) or a control virus (OV-Fc). Compared with OV-Fc, OV-CXCR4-A treatment remodeled the tumor vasculature, inhibited recruitment of VEGF-producing myeloid-derived suppressor cells, and disrupted the proangiogenic microenvironment. These changes enhanced infiltration of adoptively transferred TCRTAG T cells within the perivascular niche, correlating with improved antitumor activity and survival. Collectively, our findings demonstrate that CXCR4 blockade-mediated reprogramming of the perivascular tumor microenvironment promotes effective T-cell trafficking and function, providing a mechanistic rationale for combining oncolytic virotherapy with adoptive cell transfer in OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.